Product Name:
TRIM33-pS1119
Product Number:
ab-pk836
Target Full Name: Transcription intermediary factor 1-gamma
Target Alias: FLJ11429; KIAA1113; PTC7; Ret-fused gene 7; RET-fused gene 7 protein; RFG7; Rfg7 protein; TRIM33; Tripartite motif-containing 33 (PTC7;TIF1G); TIF1GAMMA; FLJ32925; ENSG00000197323
Product Type Specific: Protein kinase phosphosite-specific antibody
Antibody Code: PK836
Antibody Target Type: Phosphosite-specific
Antibody Phosphosite: S1119
Protein UniProt: Q9UPN9
Protein SigNET: Q9UPN9
Antibody Type: Polyclonal
Antibody Host Species: Rabbit
Antibody Immunogen Source: Human TRIM33 (TIF1G) sequence peptide Cat. No.: PE-04AQB95
Antibody Immunogen Sequence: RLK(pS)DER(bA)C
Antibody Immunogen Description: Corresponds to amino acid residues R1116 to R1122; In C-terminus of kinase
Production Method: Corresponds to amino acid residues R1116 to R1122; In C-terminus of kinase
Antibody Modification: Protein kinase phosphosite-specific antibody
Antibody Concentration: 0.75 mg/ml
Storage Buffer: Phosphate buffered saline pH 7.4, 0.05% Thimerasol
Storage Conditions: For long term storage, keep frozen at -40°C or lower. Stock solution can be kept at +4°C for more than 3 months. Avoid repeated freeze-thaw cycles.
Product Use: Western blotting | Antibody microarray
Antibody Dilution Recommended: 2 µg/ml for immunoblotting
Antibody Potency: Very strong immunoreactivity with immunogen peptide on dot blots.
Antibody Species Reactivity: Human
Antibody Positive Control: The observed molecular mass of the processed target protein on SDS-PAGE gels is reported to be around 130-150 kDa.
Antibody Specificity: High
Antibody Cross Reactivity: No significant cross-reactive proteins in HepG2 and MCF7 cells, except for medium 75 and ~48 kDa immunoreactive proteins.
Related Product 1: TRIM33-pS1119 blocking peptide
Scientific Background: TRIM33 (TIF1g) is a protein-serine/threonine kinase of the Atypical group and TIF1 family. It functions as an E3 ubiquitin-protein ligase to promote SMAD4 ubiquination, nuclear exclusion, and degradation via the ubiquitin proteasome pathway. In particular, the TRIM33 protein inhibits the SMAD4 transcriptional responses to the TGF-beta/BMP signalling cascade, a key transducer of mitogenic signals. This is accomplished through the ubiquination and subsequent degradation of SMAD4, which prevents the formation of a transcription factor complex between SMAD4, SMAD2, and SMAD3. Therefore, TRIM33 plays a critical role in the regulation of cell proliferation as it influences cellular responsiveness to TGF-beta/BMP signalling. In addition, a protein complex consisting of the TRIM33, SMAD2, and SMAD3 proteins promotes the erythroid differentiation of hematopoietic stem/progenitor cells. It is predicted that the TRIM33-SMAD2/3 and SMAD4-SMAD2/3 protein complexes function as complementary effectors in the regulation of hematopoietic cell fate as mediated by the TGF-beta signalling pathway. TRIM33 appears to be an oncoprotein (OP) and a tumour suppressor protein (TSP). Several gain-of-function mutations affecting the TRIM33 gene have been observed in cancer patients, many involving chromosomal rearrangements with the TRIM33 gene.
